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INTRA-ARTICULAR HYALURONATE EFFICACY 
AND SAFETY IN TREATMENT OF KNEE OA 
t Moiler, C Moragues, N Marti, JJ Alegre 
/nstituto Poa/ de Reumato/ogia. Barce/ona 
Aim: The aim of this study was to assess the efficacy, the dur- 
ation of the efficacy and safety of intra-articular hyaluronate treat- 
ment in 40 patients with mild to moderate CA of the knee (2-3 
degree Keligren). 
Patients and Methods: Treatment was one intra-articular injec- 
tion of a 1% sodium hyaluronate in 2 ml buffer solution (OSTENIL) 
per week for 5 consecutive weeks; 40 patients (32 females and 8 
males, with a weight average of 64.4 kg and 56.8 year old mean) 
were followed for 6 months to assess efficacy, safety, and patient 
satisfaction, and was realized a wash out period for the CA treat- 
ment. An X-ray was taken at baseline. Periodic controls for the 
Lequesne index, pain (visual analogue scale), and subjective 
efficacy were carried out. 
Results: At baseline, 87.5% of the patients showed a total inca- 
pacity in one of the minimum daily life activities, assessed by 
Lequesne index. At the end of the study the efficacy variables, 
showed an absolute improvement in97.5% of the patients. For all 
variables, the results were statistically significant in the evolution 
analysis for all visits (Friedman p<O.001 in all comparisons). Ninety 
five percent (95%) of the patients assessed treatment efficacy as 
very good or excellent, and the treatment showed a total safety 
during the study. 
Conclusions: These results show that the intra-articular treat- 
ment of knee CA process, with 5 intra-articular injections of 
OSTENIL is safe and effective, with significant improvements in 
all the studied indices (97.5%) and this improvement was main- 
tained until the end of the study period (6 months). 
Conclusion: Ultimately, the overriding benefit of this study was 
that effective CA pain/stiffness management may be achieved 
through methods other than those of potentially harmful drug 
regimens. 
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MEASUREMENT AND IMPACT OF THE ACETABULAR 
ANTEVERSION IN THE OSTEOARTHRITIS OF THE HIP 
S Terver, A Worcel, H Dechambre, J Y H~ry, G Poumarat, 
G Vanneuville 
C.H.U. Clermont-Ferrand France 
The anatomical factors may affect the evolution of osteoarthritis. 
We tested the signification of the orientation of the acetabulum in 
the appearance of the osteoarthritis of the hip. 
Methods: An original method of measurement of the anteversion 
of the acetabulum was developed by one of us. Its value was 
tested in normal and pathologic subjects by correlation intra 
observer and intra patients. We used it in 327 hips affected with 
osteoarthritis and 36 hips not affected but examined for other 
reasons. Were also measured the neck shaft angle and the 
femoral neck antetorsion using Dunlap method. 
Results: No correlation was found between neck orientation and 
osteoarthritis of the hip; on the other hand, a significant correla- 
tion was noted between acetabular anteversion and osteoarthri- 
tis of the hip at a 0.1% confidence level. The age at diagnosis 
was not found a significant factor. 
Conclusions: Anteversion of the acetabulum, if correctly meas- 
ured, appears as a significant factor in the pathogenesis of 
osteoarthritis of the hip. 
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EFFECT OF A TOPICAL HERBAL OINTMENT ON 
OSTEOARTHRITIS OF THE HAND AND KNEE: A 
RANDOMIZED CONTROLLED CLINICAL TRIAL 
HA Gemmell BH Jacobson, BM Hayes 
Oklahoma State University, Stillwater, Oklahoma and 
Intemational Research Consortium, Tulsa Oklahoma, USA 
Aim: The aim of this study was to compare the efficacy of an 
experimental osteoarthritis (CA) herbal-based, topical ointment 
(ARP TM) and a placebo ointment in the relief of osteroarthritic pain 
and stiffness of the hands and knees in patients diagnosed with 
CA. 
Methods: Subjects (N=30) were assigned to an experimental (EX) 
or a placebo (PL) group. For 42 consecutive days, applied the 
placebo or the experimental ointment o the affected site and 
recorded their level of pain and stiffness on visual analogue 
scales (VASs). Based on a previously study, data were separated 
into two categories: days 1 - 21 vs. days 22 - 42, and analyzed 
for between and within group differences. 
Results: The subjects characteristics were: mean age 60.4 yr. 
(SD= 11.6), height 65.54 in. (SD=3.2), and weight 172.5 Ib 
(SD=66.7). Significant differences in both pain (p=0.O03) and stiff- 
ness (p=0.0008) were found between the first 21 days and the last 
21 days of application for the EX group but not for the PL group. 
Analysis of gain scores between the EX and PL group yielded sig- 
nificant differences in both pain (p=0.026) and stiffness (p=0.042). 
No significant differences were found between gender for either 
pain or stiffness and no significant differences were found 
between hands and knees for pain or stiffness. 
PB25 
MODIFICATION OF OSTEOARTHRITIS BY 
ELECTROMAGNETIC FIELD EXPOSURE 
D. McK. Ciombor, R. K. Aaron, B. Simon 
Department of Orthopaedics, Brown Medica/ School 
Providence, R/, USA 
Hartley guinea pigs spontaneously develop arthritis that bears 
morphological, biochemical, and immunohistochemical similari- 
ties to osteoarthritis. It is characterized cartilage lesions by 12 
months of age and severe cartilage fibrillation and subsequent 
eburnation by 18 months of age. This study examines the effect 
of treatment with an electromagnetic field (EMF) upon the 
morphological progression of osteoarthritis in this animal model. 
Methods: Hartley guinea pigs were exposed to EMF for lh/day for 
6 months beginning at 12 months of age. Control animals were 
treated identically but without EMF exposure. Tibiat articular car- 
tilage was examined with histologicaVhistochemical grading of 
the severity of arthritis and by immunohistochemistry forcartilage 
neoepitopes 3B3(-) and BC-13, reflecting enzymatic leavage of 
aggrecan, and by immunoreactivity to collagenase (MMP 13) and 
stromelysin (MMP 3). Immunoreactivity o TGFJ~, IL-1, and IRAP 
antibodies was examined to suggest possible mechanisms of 
EMF activity. 
Results: EMF treatment preserved the integrity of articular carti- 
lage and retarded the development of osteoarthritic lesions. This 
observation was supported by a reduction in the cartilage neoepi- 
topes 3B3(-) and BC-13 and suppression of the matrix-degrading 
enzymes, collagenase and stromelysin. Cells immunopositive to 
IL-1 were decreased in number, while IRAP positive cells were 
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increased in response to treatment. EMF treatment markedly 
increases the number of cells immunopositive to TGF~. 
Conclusions: Treatment with EMF appears to be disease 
modifying in this model of osteoarthritis. Since TGF~ is believed 
to upregulate gene expression for aggrecan, downregulate matrix 
metalloprotease and IL-1 activity, and upregulate inhibitors of 
matrix metalloprotease (TIMP), the stimulation of TGF~ may be a 
mechanism through which EMF favorably affects cartilage 
homeostasis. 
PB26 
THE EFFECT OF ZlNTONA EC (A GINGER EXTRACT) ON 
SYMPTOMATIC GONARTHRITIS 
I. Wialer. D. Caspi, I Grotto, M Yaron 
Department of Reumatology, Ichilov Hospital, TeI-Aviv, Israel 
Aim: Evaluation of the effect of a Ginger extract (Zintona EC) on 
gonarthritis. 
Methods: 20 patients ( 4 men and 16 women) with symptomatic 
gonarthritis (ACR criteria) aged 43-82 years were included after 
randomisation in a double-blind placebo-controlled cross-over 
study of 6 months duration. The treatment group was given a 
Ginger Extract (250 mg of Zingiberis Rhizoma per capsule, qid), 
while the placebo group received the same number of identical 
looking capsules per day The cross-over occurred after 3 months 
of therapy. Results were evaluated by a 100ram visual analog 
scale (VAS) of pain in movement and of handicap. 
Results: Twelve patients completed the entire study period 
while 7 patients dropped out due to inefficacy (4 and 3 while on 
placebo and Zintona respectively) and one patient dropped out 
because of heartburn (while on Zintona). During the first 3 months 
of the trial, mean VAS of pain decreased from 77.5 to 46.5 
(p<0.028) and from 82.1 to41.8 (p<0.006) in both the Zintona and 
placebo arms respectively. After cross-over patients allocated 
from placebo to Zintona further decreased their VAS to 12.3 
(p<0.01) whereas in patients reallocated to placebo, VAS returned 
to its baseline mean level. VAS of handicap was very similar. 
Conclusions: Zintona was as effective as placebo during the first 
3 months study but after cross-over at the end of 6 months study 
the Ginger group showed a significant superiority over the 
placebo group (p<0.001). 
PB27 
EFFICIENCY OF PREPARATION ALPHLUTOP FOR 
OSTEOARTHRITIS 
D Kartvelishvili, R. Akhviediani, L. Shaiamberidze, 1.Gvlchia 
The Science and Practise Center Of Reumatology, 
St Andronicashvili, Tblisi 
Aim: The aim of this study was to determine the efficiency 
and sustainability of preparation Alphlutop (produced by 
"Biotechnos", Romania) for treatment of osteoarthritis (OA). 
Methods: Open clinical testing of the preparation was carried out 
on 44 patients. The majority of tested were women (95.8 %) of 
average age 52.8±2.7 years with a positive diagnosis of OA of 
knee and/or hip joints, basically at the II radiological stage and 
with the I degree of functional deficiency of joints. The patients of 
group I (with OA without reactive synovitis n = 20) received intra- 
muscular injections of Alphlutop 1 ml per day (for 21 days). The 
patients of group II (with OA of knee joints with reactive synovitis; 
n= 24) received primarily intra-articular injections of Alphlutop 
twice a week (total 6 injections), then intramuscular injections 
1 ml per day (during 21 days). 
Results: The preparation has had a positively favorable ffect on 
all the parameters: it decreased intensity of pain during move- 
ment, starting point, while moving and at rest, lessened the 
period of covering 50 meters and decreased defiguration of knee 
joints. Evaluation of the obtained results showed a favorable 
effect in 80.0 % of cases in group I and in 77.5 % of cases in 
group II. Nevertheless, a larger gradient of major improvement 
was registered in group II than in group I (20.8 % and 10.0% 
correspondingly). In 6.8 % of cases side-effects were noticed 
(rashes, itchiness, increased swelling of joints). 
Conclusions: Based on the conducted research a deduction can 
be drawn on the combination of a high therapeutic effect and 
good sustainabitity of preparation Atphlutop. 
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THE ROLE OF THE PERIOSTEAL FLAP IN THE 
CHONDROCYTE TRANSPLANTATION 
K Kajitani, M Ochi, Y Uchio, K Kawasaki, S Maniwa, 
S Furukawa 
The Department of Orthopaedics, Shimane Medical Universi~ 
tzumo, Japan 
Aim: The aim of this study was to determine the role of a 
periosteal flap in chondrocyte transplantation for the treatment of 
an articular cartilage defect. 
Methods: A cartilage defect was created on the patellar groove 
of the rabbit knee. The defect was filled with chondrocytes cul- 
tured in collagen gel, and was covered with a periosteal flap 
whose cambium layer was facing the patella (P group), or facing 
down against the bone marrow (M group). The same defect was 
covered with a periosteal flap which was frozen and thawed three 
times (F group), and an artificial collagen film (C group). 
Results: At 3 and 6 months, the defects were filled with repara- 
tive tissues that showed a smooth surface and resembled hyaline 
cartilage in the P, M and F groups. There were no significant 
differences between the reparative tissues in the three groups 
histologically, immunohistochemically, biochemically, and bio- 
mechanically. Although the collagen film fell down into the defect 
and the reparative tissue had a fibrous tissue-like appearance in 
the C group. 
Conclusions: These results showed that the role of the periosteal 
flap does not have a beneficial humoral or cellular effect on the 
formation of reparative tissue, suggesting that the periosteal flap 
might act as only a mechanical barrier to prevent leakage of the 
grafted chondrocytes. 
PB30 
BARRIERS TO APPROPRIATE UTILISATION OF HIP/KNEE 
JOINT REPLACEMENTS 
C Sanders, J Donovan, J Chard, P Dieppe 
MRC HSRC, Bristol, UK 
Introduction: While total joint replacement (TJR) is an effective 
treatment for severe joint disease, research evidence consist- 
ently shows variation in provision and thus potential for unmet 
need. We investigated barriers to appropriate utilization of TJR. 
